Cargando…
Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis
The available data, including experimental studies, clearly indicate an excessive intravascular activation of circulating platelets in multiple sclerosis (MS) and their hyper-responsiveness to a variety of physiological activators. Platelet activation is manifested as an increased adhesion and aggre...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406904/ https://www.ncbi.nlm.nih.gov/pubmed/30717273 http://dx.doi.org/10.3390/cells8020110 |
_version_ | 1783401431861035008 |
---|---|
author | Saluk-Bijak, Joanna Dziedzic, Angela Bijak, Michal |
author_facet | Saluk-Bijak, Joanna Dziedzic, Angela Bijak, Michal |
author_sort | Saluk-Bijak, Joanna |
collection | PubMed |
description | The available data, including experimental studies, clearly indicate an excessive intravascular activation of circulating platelets in multiple sclerosis (MS) and their hyper-responsiveness to a variety of physiological activators. Platelet activation is manifested as an increased adhesion and aggregation and is accompanied by the formation of pro-thrombotic microparticles. Activated blood platelets also show an expression of specific membrane receptors, synthesis many of biomediators, and generation of reactive oxygen species. Epidemiological studies confirm the high risk of stroke or myocardial infarction in MS that are ischemic incidents, strictly associated with incorrect platelet functions and their over pro-thrombotic activity. Chronic inflammation and high activity of pro-oxidative processes in the course of MS are the main factors identified as the cause of excessive platelet activation. The primary biological function of platelets is to support vascular integrity, but the importance of platelets in inflammatory diseases is also well documented. The pro-thrombotic activity of platelets and their inflammatory properties play a part in the pathophysiology of MS. The analysis of platelet function capability in MS could provide useful information for studying the pathogenesis of this disease. Due to the complexity of pathological processes in MS, medication must be multifaceted and blood platelets can probably be identified as new targets for therapy in the future. |
format | Online Article Text |
id | pubmed-6406904 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64069042019-03-19 Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis Saluk-Bijak, Joanna Dziedzic, Angela Bijak, Michal Cells Review The available data, including experimental studies, clearly indicate an excessive intravascular activation of circulating platelets in multiple sclerosis (MS) and their hyper-responsiveness to a variety of physiological activators. Platelet activation is manifested as an increased adhesion and aggregation and is accompanied by the formation of pro-thrombotic microparticles. Activated blood platelets also show an expression of specific membrane receptors, synthesis many of biomediators, and generation of reactive oxygen species. Epidemiological studies confirm the high risk of stroke or myocardial infarction in MS that are ischemic incidents, strictly associated with incorrect platelet functions and their over pro-thrombotic activity. Chronic inflammation and high activity of pro-oxidative processes in the course of MS are the main factors identified as the cause of excessive platelet activation. The primary biological function of platelets is to support vascular integrity, but the importance of platelets in inflammatory diseases is also well documented. The pro-thrombotic activity of platelets and their inflammatory properties play a part in the pathophysiology of MS. The analysis of platelet function capability in MS could provide useful information for studying the pathogenesis of this disease. Due to the complexity of pathological processes in MS, medication must be multifaceted and blood platelets can probably be identified as new targets for therapy in the future. MDPI 2019-02-01 /pmc/articles/PMC6406904/ /pubmed/30717273 http://dx.doi.org/10.3390/cells8020110 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Saluk-Bijak, Joanna Dziedzic, Angela Bijak, Michal Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis |
title | Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis |
title_full | Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis |
title_fullStr | Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis |
title_full_unstemmed | Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis |
title_short | Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis |
title_sort | pro-thrombotic activity of blood platelets in multiple sclerosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406904/ https://www.ncbi.nlm.nih.gov/pubmed/30717273 http://dx.doi.org/10.3390/cells8020110 |
work_keys_str_mv | AT salukbijakjoanna prothromboticactivityofbloodplateletsinmultiplesclerosis AT dziedzicangela prothromboticactivityofbloodplateletsinmultiplesclerosis AT bijakmichal prothromboticactivityofbloodplateletsinmultiplesclerosis |